Keliximab

Keliximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (primate/human)
Target	CD4
Clinical data
Routes of; administration	intravenous
ATC code	none;
Identifiers
CAS Number	174722-30-6 ;
ChemSpider	none;
	(what is this?) (verify)

Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]

References

Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC (October 1998). "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma". Lancet. 352 (9134): 1109–13. doi:10.1016/S0140-6736(97)12261-9. PMID 9798587.
"Proposed INN List" (PDF). WHO Drug Information. 10 (Number 4). 1996.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC (October 1998). "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma". Lancet. 352 (9134): 1109–13. doi:10.1016/S0140-6736(97)12261-9. PMID 9798587.

[2] "Proposed INN List" (PDF). WHO Drug Information. 10 (Number 4). 1996.